Schuetz EG - Search Results

1

Identification of functionally variant MDR1 alleles among European Americans and African Americans.

Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Kim RB, et al. Among authors: schuetz jd, schuetz eg. Clin Pharmacol Ther. 2001 Aug;70(2):189-99. doi: 10.1067/mcp.2001.117412. Clin Pharmacol Ther. 2001. PMID: 11503014

2

Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.

Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Yasuda K, et al. Among authors: schuetz jd, schuetz eg. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. doi: 10.1124/jpet.102.037549. J Pharmacol Exp Ther. 2002. PMID: 12235267

3

Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms.

Schuetz EG, Furuya KN, Schuetz JD. Schuetz EG, et al. Among authors: schuetz jd. J Pharmacol Exp Ther. 1995 Nov;275(2):1011-8. J Pharmacol Exp Ther. 1995. PMID: 7473127

4

Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.

Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD. Lecureur V, et al. Among authors: schuetz jd, schuetz eg. Mol Pharmacol. 2000 Jan;57(1):24-35. Mol Pharmacol. 2000. PMID: 10617675

5

Mdr1 limits CYP3A metabolism in vivo.

Lan LB, Dalton JT, Schuetz EG. Lan LB, et al. Among authors: schuetz eg. Mol Pharmacol. 2000 Oct;58(4):863-9. doi: 10.1124/mol.58.4.863. Mol Pharmacol. 2000. PMID: 10999959

6

A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression.

Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB. Marzolini C, et al. Among authors: schuetz jd, schuetz eg. Mol Endocrinol. 2007 Aug;21(8):1769-80. doi: 10.1210/me.2007-0025. Epub 2007 May 22. Mol Endocrinol. 2007. PMID: 17519356

7

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. Ekins S, et al. Among authors: schuetz jd, schuetz eg. Mol Pharmacol. 2002 May;61(5):964-73. doi: 10.1124/mol.61.5.964. Mol Pharmacol. 2002. PMID: 11961113

8

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. Ekins S, et al. Among authors: schuetz jd, schuetz eg. Mol Pharmacol. 2002 May;61(5):974-81. doi: 10.1124/mol.61.5.974. Mol Pharmacol. 2002. PMID: 11961114

9

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

Schuetz EG, Beck WT, Schuetz JD. Schuetz EG, et al. Among authors: schuetz jd. Mol Pharmacol. 1996 Feb;49(2):311-8. Mol Pharmacol. 1996. PMID: 8632764

10

P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.

Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. Schuetz EG, et al. Among authors: schuetz jd. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4001-5. doi: 10.1073/pnas.93.9.4001. Proc Natl Acad Sci U S A. 1996. PMID: 8633005 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page